ZOFRAN is indicated for the prevention of nausea and vomiting associated with:

  • highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2
  • initial and repeat courses of moderately emetogenic cancer chemotherapy
  • radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen

ZOFRAN is also indicated for the prevention of postoperative nausea and/or vomiting.

Short-acting, lipophilic sedative/hypnotic; causes global CNS depression, presumably through agonist actions on GABAa receptors